Issue Date: January 23, 2012
Pfizer, Medivation Halt Alzheimer’s Pact
Pfizer and Medivation are ending their collaboration for the Alzheimer’s disease drug candidate dimebon and discontinuing development of the compound. The news comes after a Phase III study showed that giving the drug in combination with Pfizer’s Aricept did not improve cognitive ability or daily functioning in people with Alzheimer’s disease. In 2008, Pfizer paid $225 million for access to dimebon and agreed to pay Medivation upward of $500 million as the drug candidate progressed. The big pharma firm also took on 60% of the development expenses for the failed drug.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society